Co-infection with talaromycosis and tuberculosis is common, with microbiology-confirmed tuberculosis coinfection seen in 22% of patients [3], and presents a therapeutic challenge in that rifampicin as a potent CYP3A4 inducer reduces itraconazole concentration by 60% [18]. The gene discussed is CYP3A4; the disease is coinfection.